

# Curriculum Vitae

## **Davide Papola, MD, PhD**

|                       |                        |
|-----------------------|------------------------|
| <b>Born</b>           | August 9, 1987         |
| <b>Place of birth</b> | L'Aquila, Italy        |
| <b>Residence</b>      | Verona, Italy          |
| <b>Email</b>          | davide.papola@univr.it |

Verona, 1/1/2026

## Index

|   |    |
|---|----|
| Current position.....   | 3  |
| Qualifications.....   | 4  |
| Clinical activity .....   | 5  |
| Scientific activity.....  | 6  |
| Metrics .....   | 6  |
| Leading or participating in the activities of a research group characterized by national or international collaboration. .....                                | 7  |
| Responsibility for scientific studies and research entrusted by qualified public or private institutions.....   | 11 |
| Scientific responsibility for international and national research projects accepted for funding on the basis of competitive calls involving peer review ..... | 13 |
| Serving on editorial boards of scientific journals.....   | 14 |
| Formal award of research positions (fellowships) at qualified foreign universities and research institutes.....   | 15 |
| Achievement of awards and honors for scholarly activity, including membership in prestigious academies .....  | 16 |
| Specific professional experience characterized by research activities .....   | 17 |
| Scientific publications .....   | 21 |
| <i>Peer-reviewed scientific articles published in international journals</i> .....  | 21 |
| <i>Articles in international non-indexed journals</i> .....   | 33 |
| <i>Scientific articles Italian national journals</i> .....  | 33 |
| <i>Book chapters</i> .....  | 34 |
| <i>Posters and abstracts presented at national and international conferences</i> .....  | 34 |
| <i>Oral presentations at scientific conferences</i> .....   | 36 |
| <i>Organiser of national and international scientific events</i> .....  | 38 |
| <i>Moderator of scientific sessions at national and international conferences</i> .....   | 38 |

**Current position**

|  |  |
|--|--|
| October 2025   | Assistant Professor  |
| - present  | <ul style="list-style-type: none"><li>- WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona (Italy).</li></ul> |
| Consultant   |  |
| <ul style="list-style-type: none"><li>- Inpatient Service,<br/>Verona University Hospital Trust.<br/>Policlinico Giambattista Rossi,<br/>Piazzale L.A. Scuro 10, 37134, Verona (Italy)</li></ul> |  |

## **Qualifications**

28/06/2021 Doctor of Philosophy

Doctorate program in Neurosciences, Biomedicine, and Movement Sciences (XXXIII/2017 cycle), University of Verona (Verona, Italy).

Defense title: “*The RE-DEFINE project and the effectiveness of SH Plus in preventing mental disorders in refugees and asylum seekers resettled in Europe: a multicentre randomized controlled trial*”

Supervisor: Professor Corrado Barbui

28/06/2021 Doctor Europaeus

European Commission

27/02/2019 License to practice as a Psychotherapist

Medical Council of Verona (Verona, Italy)

10/08/2018 Specialization in Psychiatry

University of Verona (Verona, Italy)

Thesis title: “*Focused psychosocial interventions for children in low-resource humanitarian settings: a systematic review and individual participant data meta-analysis*”

Supervisor: Professor Corrado Barbui

Grade: 70/70 cum Laude

05/03/2013 License to practice as Medical Doctor (license number: 8843)

Medical Council of Verona (Verona, Italy)

19/07/2012 Medical Degree

University of Verona (Verona, Italy)

Thesis title: “*Efficacia e tollerabilità della paroxetina nella depressione maggiore unipolare: revisione sistematica e metanalisi Cochrane delle sperimentazioni randomizzate*”.

Supervisor: Professor Corrado Barbui

Grade: 110/100 cum Laude

07/2006 High School Diploma

Liceo Scientifico Statale “Andrea Bafile” (L’Aquila, Italy)

### **Clinical activity**

2025 – Consultant, Clinical Unit of Adult Psychiatry – Policlinico G.B. Rossi, Azienda Ospedaliera Universitaria Integrata di Verona, Italy

2021 – 2022 Consultant psychiatrist at the therapeutic community “*Insieme verso nuovi orizzonti*” (Together Towards New Horizons), Trento, Italy.

2018 – 2022 Private practice psychiatrist and psychotherapist, Verona, Italy.

2018 – 2022 “Villa Santa Giuliana” Clinic (Verona, Italy), freelance psychiatrist.

2013 – 2018 Trainee Psychiatrist in the South-Verona Community Mental Service (CMHS), providing mental health care at both in-patient, outpatient and community levels. Main activities:

- Clinical and therapeutic management of community patients suffering from severe mental disorders, including supportive interventions, medication treatments, follow-up visits, in consultation with other health and social agencies (e.g. social services). Under supervision.
- Clinical and therapeutic management of patients with severe mental disorders admitted to the inpatient psychiatric ward.
- Consultation activity in the emergency room and in other medical departments during on-call shifts.
- Consultation activity with other hospital departments for the joint clinical management of patients suffering from psychiatric disorders in the psychosomatic area.

**Scientific activity**

**Metrics**

Scopus

| Documents | Citations | H-Index |
|-----------|-----------|---------|
| 106       | 2737      | 30      |

Web of Science

| Documents | Citations | H-Index |
|-----------|-----------|---------|
| 92        | 2237      | 28      |

Google Scholar

| Documents | Citations | H-Index |
|-----------|-----------|---------|
| 116       | 3783      | 33      |

**Leading or participating in the activities of a research group characterized by national or international collaboration.**

1. Participation as recruiting physician and data manager for the national multicenter observational, cross-sectional scientific study of the “QTc Study” (coordinator: Prof. Michela Nosé).

01-06-2014 to 01-03-2015

2. Member of the STAR Network Consortium – *Servizi Territoriali Associati per la Ricerca* (Associated Territorial Services for Research), which involves more than 35 psychiatric services all over Italy. I am in charge of coordinating the research activities, periodically updating the group members, and supervising the quality of the scientific production derived from the collected data.

01-06-2015 to present

3. Participation in patient recruitment for the observational study entitled: “Long-acting antipsychotics: patient characteristics and prescribing attitudes in the Italian territory. A multicenter observational study” (“DEPOT” study). 36 Italian psychiatric services were involved. Coordinator: Prof. Corrado Barbui.

15-12-2015 to 01-08-2018.

4. Core member of the Cochrane Global Mental Health (CGMH) group based in Verona. CGMH is a partnership that brings together the five Cochrane mental health groups: "Common Mental Disorders", "Dementia and Cognitive Improvement", "Developmental, Psychosocial and Learning Problems", "Drugs and Alcohol" and "Schizophrenia". I participate in the work of the group as a reviewer and methodologist. For more information see this link: <https://globalmentalhealth.cochrane.org>.

01-01-2017 to present.

5. Member of the international research group "GRADE Working Group" (Chair: Prof. Holger Schunemann). The “Grading of Recommendation, Assessment, Development and Evaluation” (GRADE) method was developed in 2000 at McMaster University (Hamilton, Canada) and consists of a methodological system for grading the quality of scientific evidence. GRADE has been adopted by more than 100 organizations, including the World Health Organization (WHO), the National Institute for Health and Care Excellence (NICE), the American College of Physicians (ACP), and the Centers for Disease Control and Prevention (CDC). I began studying GRADE methodology in 2017 during a fellowship at McMaster University. Since then, I have contributed to the dissemination of the GRADE method internationally through scientific publications and nationally through teaching activities.

01-04-2017 to present

6. Participation in patient recruitment and team member in charge of the RE-DEFINE (Refugee Emergency: DEFining and Implementing Novel Evidence-based psychosocial interventions) study, involving eight European partners, Turkey, and the World Health Organization (Geneva), with data collection and analysis tasks.

01-12-2017 to 04-12-2020

7. Founder in 2019 and since then Principal Investigator of the section "Anxiety disorders" project "Metapsy". Metapsy (<https://www.metapsy.org/>) provides free access to meta-analytic databases developed by academic researchers over the last decades; the project is directed by Prof. Pim Cuijpers (Vrije Universiteit, Amsterdam). All Metapsy databases are compiled according to rigorous scientific standards. The databases are regularly updated, and each research step is documented in open-source repositories. The goal of Metapsy is to create a central hub for meta-analytic research domains (MARDs) that will allow all areas of psychotherapy research and, soon, pharmacology to be analyzed in a consistent, transparent, and accessible manner. The "Anxiety Disorders" domain, which I lead as principal investigator, is, after the "Depression" domain led by Prof. Pim Cuijpers, the largest domain of the entire project. It includes all randomized trials that have investigated the efficacy of psychotherapy (versus an inactive control, a drug, or another psychotherapy) for the treatment of "panic disorder", "generalized anxiety disorder", "social phobia", "transdiagnostic anxiety disorders", and "specific phobias". Currently, the database I manage and maintain consists of 634 randomized trials that have been identified, cataloged, data extracted, and in most cases, analyzed and published.

01-04-2019 to date.

8. Participation in patient recruitment and member of the working group responsible for the VESPA study (Vortioxetine in the Elderly vs. SSRIs: a Pragmatic Appraisal), involving 11 Territorial Psychiatric Services in Italy and the IRCCS Mario Negri (Milan), with data collection and analysis tasks.

19-09-2019 to 19-09-2023

9. Member of the working group that prepared the national document "Recommendations for the management of the COVID-19 epidemic and associated mental distress factors in people with intellectual disability and autism with high and very high support needs". The document was produced under the auspices of the "Italian Society for Neurodevelopmental Disorders" (SIDiN).

27-04-2020 to 27-04-2020

10. Coordinator for the University of Verona of the COMET- Covid19 Mental Health Survey. The Psychiatry Section of the Department of Neurosciences, Biomedicine and Movement of the University of Verona, together with 11 other research institutes around the world, participates in the international study COMET- Covid19 Mental Health Survey, sponsored by the Vrije Universiteit in Amsterdam. Through a questionnaire, the research aims to assess symptoms of psychological distress during the COVID-19 emergency and whether they are associated with characteristics such as gender, age, experience and lived experience of the crisis, or people's view of society. The project will assess the occurrence and evolution over time of psychiatric symptoms (anxiety, depression, post-traumatic stress disorder) in people living in the Netherlands, Italy, Switzerland, Spain, Germany, Australia, France, Turkey, Indonesia, and China.

01-09-2020 to present

11. Founding member of the international research group Library of Guidance for Health Scientists (LIGHTS). LIGHTS is a peer-supported initiative to improve access to and use of methodologically relevant guidelines for health professionals. Through my presence in the working group, the sensitivity of this project to the topic of mental health has been enhanced. LIGHTS features 1690 articles, including tutorials, reporting guidelines, quality guidelines, and methodological guides. In collaboration with McMaster University (Canada) and the University of Basel (Switzerland). For further information: [www.lights.science](http://www.lights.science).

01-04-2022 to present.

12. Member of the “Mental Health for All lab” directed by Professor Vikram Patel at the Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, as a Marie Skłodowska Curie Postdoctoral Fellow. Personal page: <https://mentalhealthforalllab.hms.harvard.edu/people/davide-papola>.

01-10-2022 to 30-09-2024.

13. Participation in patient recruitment and as a member of the coordinating center in the multi-center national research project “DISCARD (DISContinuation of Antidepressants in Remitted Depression): Safe discontinuation of antidepressants in individuals with clinically remitted depression or anxiety disorders” of 24 months duration (EU trial number: 2023-509377-23-00; PI: Dr. Giovanni Ostuzzi) funded by PRIN: Progetti di Ricerca di rilevante Interesse Nazionale - Call 2022 PNRR Prot. P2022LY3RF. The multicenter project involves the centers of the University of Verona, the University of Padua, the University of Milan-Bicocca, the University of Milan, and the University of Magna Graecia of Catanzaro.

18-10-2023 to present.

14. Member of the international working group that is leading the implementation of the “Verona-Lugano (VELUT) tool.” The VELUT group is composed of experts in the field of Global Mental Health, such as Prof. Crick Lund, Prof. Mark Jordans, Prof. Marit Sijbrandij, Prof. Marianna Purgato, and Prof. Corrado Barbui (Principal Investigator). In this context I am contributing to the development of the VELUT, a tool for the analysis of randomized trials testing psychosocial interventions for people with mental illness. Specifically, the purpose of VELUT is to enable the discrimination of trials aimed at the treatment of mental illness, the prevention of mental illness, or the promotion of mental health, to facilitate the cataloging of such interventions, and to promote the development of more consistent scientific evidence in this area.

01-11-2023 to 01-12-2025

15. Member of the national "Italian GRADE Working Group" (Contact: Prof. Holger Schunemann). As part of the international GRADE network since 2017 (see above), I was invited to be a founding member of the Italian GRADE Working Group, established in December 2023. The Italian GRADE Networking Group is a network of Italian professionals who are experts in applying the GRADE method for producing guidelines in health care. Through my involvement, I can influence the development and application of the GRADE methodology by contributing content relevant to mental health issues, given my clinical background as a mental health professional and all the other colleagues in the working group who come from other clinical settings.

10-12-2023 present

16. Member of the Scientific Advisory Board of the project entitled “PEACE – Precision Evidence-based psychological Aid for Children in Emergency”. Funded by the European Commission under the ERC scheme, “consolidator grant” to Prof Marianna Purgato.

19-01-2026 present

**Responsibility for scientific studies and research entrusted by qualified public or private institutions**

1. “Guideline developer” at Istituto Superiore di Sanità (ISS) for the production of the “Guideline on diagnosis and treatment of autism spectrum disorder in adults” in collaboration with Osservatorio Nazionale Autismo (OssNA) (scientific responsabilie: Dr. Maria Luisa Scattoni). Participation in the “Panel Meetings” of the working group by performing the following tasks: writing the preliminary version of the guideline scope; organizing and managing consultations with stakeholders in accordance with the adopted methodological framework; formulating PICO questions in accordance with the Technical-Scientific Committee (TSC), the Expert Panel, the Evidence Review Team, and the Economic Analysis Team; participating in Panel meetings, without voting rights; take minutes of the meetings and archive the documents produced; write preliminary and final recommendations based on the results of the discussions and decisions reached by the Expert Panel; report to the TSC on the progress of the work (access the guideline at: <https://www.iss.it/web/guest/-/snlg-homepage-consultazione>)

01-07-2018 to present.

2. Consultant to the World Health Organization (WHO). Engaged as a methodologist for a literature review to produce cost-effectiveness analyses of drug treatments for bipolar disorder.

14-06-2019 to 13-07-2019

3. Member of the World Health Organization (WHO) Evidence Review Team to synthesize and assess the quality of evidence for the document on the management of neurological and psychiatric manifestations associated with COVID-19. The work was coordinated by the WHO Department of Mental Health, Brain Health and Substance Use, and the evidence gathered was used by an international panel of experts to develop guidelines summarized in the document "Clinical Management of COVID-19. Interim guidance May 27, 2020," Chapter 15 "Management of neurological and mental manifestations associated with COVID-19," published by WHO (Geneva, Switzerland). My participation was at the invitation of Dr. Tarun Dua, Director of the Brain Health Unit of the WHO Department of Mental Health, Brain Health and Substance Use.

01-03-2020 to 27-04-2020

4. Consultant to the World Health Organization (WHO). Engaged as a methodologist to apply the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology to WHO mental health guidelines.

28-05-2021 to 03-06-2021.

5. Member of the Evidence Review Team that completed the evidence synthesis document for updating the Anxiety Disorders Chapter of the World Health Organization (WHO) document "mhGAP". At the invitation of Dr. Mark van Ommeren, Director of the Mental Health Section of the WHO Department of Mental Health, Brain Health and Substance Use.

01-06-2021 to 01-10-2021

6. Coordinated a team of researchers who redesigned the mental health section of the World Health Organization (WHO) Essential Medicines List. Under my coordination, a series of documents (nine applications - four of which I prepared as first author) were prepared and submitted to the WHO Secretary of the Department of Mental Health in December 2022. After review by a selected, independent, conflict-of-interest committee of WHO experts, all the proposals were accepted. This resulted in a radical update of the list. The project was assigned to the WHO Collaborating Centre at the University of Verona, where I work, by the WHO Department of Mental Health, Brain Health and Substance Use (Director: Dr. Mark van Ommeren). Each of the applications can be accessed at this address: <https://www.who.int/groups/expert-committee-on-selection-and-use-of-essentialmedicines/24th-eml-expert-committee>.

01-10-2021 to 12-12-2022.

7. Role of "developer" and methodological support during panel meetings organized in virtual mode by the World Health Organization's Department of Mental Health for the process of updating the "mhGAP" guideline (contact person: Dr. Mark van Ommeren).

01-02-2022 to 30-09-2022

**Scientific responsibility for international and national research projects accepted for funding on the basis of competitive calls involving peer review**

1. Recipient of the grant “COOPERINT” - University of Verona. In support of the research project “Association between antipsychotic intake and life-threatening medical events” for which I spent a research period at McMaster University (Hamilton, Ontario, Canada). Grant amount: € 5000;  
01-04-2017 to 01-10-2017.
2. Grant recipient of the “International Mobility Program” - University of Verona. In support of the research project “Psychological treatment of anxiety: A meta-analytic database of randomized controlled trials” for the conduct of which I spent a research period at Vrije Universiteit (Amsterdam, Netherlands). Grant amount: € 3500;  
18-03-2019 to 11-10-2019
3. Awardee of Marie Skłodowska-Curie Actions, Individual Fellowship - Global Fellowship. Funding awarded by the European Commission under the call “HORIZON-MSCA-2021- PF-01” for the grant proposal entitled: “Dismantling, REdialing, personalizing, and implementing task SHIFTing psychosocial interventions to treat and prevent common mental disorders in low-resource settings.” Project duration: October 1, 2022 - September 30, 2025. Grant amount: € 265099.19. For the implementation of this project I spent the first two years of the fellowship at the Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, in Boston, MA (USA), working in the research group of Professor Vikram Patel. For more information: <https://mentalhealthforalllab.hms.harvard.edu/people/davide-papola>;  
<https://reshiftproject.com/>  
01-10-2022 to 30-09-2025

**Serving on editorial boards of scientific journals**

1. Associate Editor for the journal BMC Psychiatry. BMC Psychiatry is an open-access, peer-reviewed journal covering a wide range of topics, including psychopharmacology, psychotherapy, and psychosocial approaches to psychiatric disorders, as well as genetics, pathophysiology, and epidemiological research. See link: <https://bmcpyschiatry.biomedcentral.com/about/editorial-board>  
01-01-2021 to present
2. Associate Editor for the journal Frontiers in Psychiatry (Schizophrenia section). Frontiers in Psychiatry is an interdisciplinary journal that focuses on translational approaches to improve treatment options for mental illness and, consequently, patient treatment outcomes. See link: <https://loop.frontiersin.org/people/1065144/overview>  
01-01-2022 to present

**Formal award of research positions (fellowships) at qualified foreign universities and research institutes**

1. Marie Skłodowska Curie Global Postdoctoral Research Fellow at the Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA (USA). Head of the Department: Professor Vikram Patel.

01-10-2022 to 30-09-2024

2. Doctoral Research Fellow at the Department of Clinical, Neuro and Developmental Psychology, Amsterdam Public Health research institute, Vrije Universiteit (Amsterdam, The Netherlands). Supervisor: Professor Emeritus Pim Cuijpers.

18-03-2019 to 10-10-2019

3. Research Fellow in the Department of Health Research Methods, Evidence, and Impact at McMaster University (Hamilton, Ontario, Canada). Supervisor: Distinguished Professor Gordon Guyatt.

01-04-2017 to 01-10-2017

**Achievement of awards and honors for scholarly activity, including membership in prestigious academies**

1. Member of the academy “Cochrane Collaboration”, registered in the web platform “Archie” since 2018, with participation in the writing of systematic reviews as a principal investigator with several publishing groups, including “Common Mental Disorders Group” and “Global Mental Health”.

02-02-2018 to present

2. Award of “Best Poster” in the “Life and Health Sciences” category of “PhD Day at the University of Verona”. Poster title: “Refugee Emergency: DEFining and Implementing Novel Evidence-based psychosocial interventions”.

06-12-2018 to 06-12-2018

3. Co-author of the winning poster for “Best e-poster” in the category “Mental health care from theory to outcome”. Congress of the European Network of Mental Health Service Evaluation (ENMESH) entitled: “Managing Mental Health System Complexity” held in Lisbon, Portugal, 6-8 June, 2019. Poster title: “Using a network meta-analysis approach to update the WHO Essential Medicine List on long-acting antipsychotics,” Poster Session II - Monitor 1.

07-06-2019 to 07-06-2019

4. Marie Skłodowska-Curie Actions, *Seal of Excellence*. Certificate awarded by the European Commission under the call H2020-MSCA-IF-2020 for the grant proposal entitled: “EIDOS. Understanding the Efficacy and mechanism of action of Interventions for preventing Depression in high-, low-, and middle-income countries”.

26-03-2021 to 26-03-2021

5. Wiley Top cited article 2022-2023 for the paper “Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.”

01-01-2022 to 31-12-2023

6. Winner of the “Psyche Award for Most Valuable Paper on Anxiety Disorders and Trauma” 2023 edition. The award was given by the Editorial Board of the Journal of Contemporary Psychotherapy for the publication of the paper “Papola et al. Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomized controlled trials. Br J Psychiatry 2022;221(3):507-519.”

19-04-2023 to 19-04-2023

### Specific professional experience characterized by research activities

1. Degree in Medicine and Surgery from the University of Verona, with a grade of 110/110 cum laude; License to practice medicine; Publication of the experimental thesis entitled: "Paroxetine versus other anti-depressive agents for depression, Cochrane systematic review and meta-analysis of the evidence-based findings from randomized controlled trials."

01-10-2006 to 19-07-2012

2. Postgraduate Degree in Psychiatry at the School of Specialization in Psychiatry of the University of Verona, with a grade of 70/70 cum laude. Publication of experimental residency thesis entitled "Focused psychosocial interventions for children in low-resource humanitarian settings: a systematic review and individual participant data meta-analysis".

08-08-2013 to 10-08-2018

3. Tutor for the course: "Postgraduate Course in Systematic Reviews and Meta-analysis for the Production of Evidence-Based Guidelines in Health Care Settings", held in Verona, Polo Universitario "Santa Marta", editions: November 25-29, 2013, April 4-8, 2016.

25-11-2013 to 15-04-2016

4. Ad-hoc reviewer for the following indexed journals: The British Medical Journal (since 2025); Neuropsychopharmacology Reviews (since 2025); Jama Psychiatry (since 2024); Schizophrenia Bulletin (since 2024); Neuroscience and Biobehavioral Reviews (since 2023); BMJ Mental Health (since 2023); Current Neuropharmacology (since 2022); The Lancet regional health - western pacific (since 2022), Evidence-Based Mental Health (since 2022); The British Journal of Psychiatry (from 2021); BMC Medicine (from 2021); Journal of Psychiatric Research (from 2021); BMC-Geriatrics (from 2021); Child and Adolescent Mental Health (from 2021); Drugs - Real World Outcomes (from 2021); Pilot and Feasibility Studies (from 2020); BMC Psychiatry (from 2020); Complementary Therapies in Medicine (from 2020); European Journal of Epidemiology (from 2019); Journal of Psychopharmacology (from 2019); Advances in Integrative Medicine (from 2019); PlosOne (from 2019); Neuropsychiatric Disease and Treatment (from 2019); The Journal of Clinical Psychiatry (since 2019); CNS Spectrum (since 2019); BMJ-Open (since 2018); Journal of Affective Disorders (since 2018); Drug Safety (since 2017); Epidemiology and Psychiatric Sciences (since 2017); Mental Health Action (since 2016); European Journal of Psychotraumatology (since 2015).

For more details: <https://www.webofscience.com/wos/author/record/543918>

01-01-2015 to present

5. Participation in the course "Phenomenological Psychopathology as the Foundation of Diagnosis, Understanding and Treatment" at the School of Phenomenological Dynamic Psychotherapy, Florence (director: Prof. Giovanni Stanghellini).

10-10-2015 to 06-03-2016

6. Participation in the course “Evidence-Based Clinical Practice workshop - How to Teach Evidence-Based Medicine” at McMaster University (Hamilton, Ontario, Canada). Course director: Prof. Gordon Guyatt.

05-06-2017 to 09-06-2017

7. Doctoral studies at the World Health Organization Collaborating Center, Department of Neuroscience, Biomedicine and Movement, University of Verona (PhD Supervisor Prof. Corrado Barbui). PhD degree awarded on 25/05/2021 with thesis dissertation entitled: “The RE-DEFINE project and the effectiveness of SH+ in preventing mental disorders in refugees and asylum seekers resettled in Europe: a multicenter randomized controlled trial ”.

01-10-2017 to 28-06-2021

8. Member of the scientific committee, lecturer and organizer of the course: “Postgraduate Course in Systematic Reviews and Metanalysis for the Production of Evidence-Based Guidelines in Health Care Settings,” held in Verona, Polo Universitario “Santa Marta”, editions: April 9-13, 2018, September 21-25, 2020, April 4-8, 2022, June 10-14, 2024.

09-04-2018 to 14-06-2024

9. Presentation of 14 scientific posters in numerous national and international congresses, including those of the following scientific societies: Italian Society of Psychopathology (SOPSI), Italian Society of Psychiatry (SIP), Cochrane Collaboration, European Psychiatric Association (EPA), Evidence-Based Research Conference (EVBRES).

16-09-2018 to present.

10. Author of the book chapter entitled “Promoting the appropriate use of psychotropic drugs”, authors Ostuzzi G, Gastaldon C, Papola D, Barbui C, within the volume “Social psychiatry in Italy: evidence and experiences” published by PaciniMedicina 2020 and edited by Andrea Fiorillo.

from 01-06-2019 to 01-11-2019

11. Research Fellow in concurrent area 06/D5, Psychiatry SSD MED/25, at the World Health Organization Collaborating Center, Department of Neuroscience, Biomedicine and Movement, University of Verona. Personal page: <https://www.dnbm.univr.it/?ent=persona&id=20415>

01-10-2020 to present.

12. Lecturer for the “Veneto Region Regional Program for Continuing Education of Health Professionals 2020.” CME accredited training event entitled: “Drug use in psychiatric settings and monitoring of adverse reactions.” Title of presentation: “Pharmacovigilance in psychiatry in the era of Evidence Based Medicine.” Presented in virtual mode, by invitation.

03-12-2020 to 03-12-2020.

13. Subject Tutor in Psychiatry MED/25 at the University of Verona starting from 2019/2020. Activities of tutor, supervisor and correlator of experimental theses in the specialization course in psychiatry at the University of Verona.  
01-02-2021 to present
14. Participation in the Summer School on “Introduction to Data Analysis with R”. The course was held at La Sapienza, University of Rome.  
24-05-2021 to 27-05-2021.
15. Master thesis supervisor for a student enrolled at the Vrije Universiteit (Amsterdam, The Netherlands), at the invitation of Prof. Pim Cuijpers. Assignment related to my involvement as principal investigator of the “Anxiety Disorders” section of the Metapsy project.  
01-10-2022 to 30-09-2023.
16. Participation in the course “Responsible Conduct of Research Program” at Harvard Medical School, Harvard University, Boston, MA (USA). The course is designed for postdoctoral fellows to explore the concepts of research ethics and individual/group responsibility in the scientific production process.  
01-10-2022 to 08-05-2024
17. Participation in the “Leadership in mental health” course. Course was held in virtual mode in November and December 2022 and at Sangath NGO in Goa, India, from January 9-13, 2023. Course director: Prof. Vikram Patel  
15-11-2022 to 13-01-2023
18. Participation in the course “Systematic review and Meta-Analysis of Individual Participant Data,” a module of the Master program “Epidemiology” at University of Utrecht, The Netherlands. Course director: Prof. Hans Reitsma.  
26-06-2023 to 30-06-2023.
19. Participation in the course “Mentor Training Workshops” at Harvard Medical School, Harvard University, Boston, MA (USA). The series of workshops is designed to provide early career researchers with useful tools for mentoring junior investigators and a curriculum to follow in building their research group.  
01-02-2024 to 01-05-2024
20. Participation in the “McMaster Advanced GRADE Workshop” course at McMaster University (Hamilton, Ontario, Canada), Department of Health Research Methods, Evidence & Impact. Course Director: Prof. Gordon Guyatt.  
07-05-2024 to 09-05-2024
21. Invited as an expert to constructively review and critique the chapter on “Generalized Anxiety Disorder” in the “DynaMed” online consultation system. DynaMed is an evidence-based online medical resource designed to provide reliable, up-to-date clinical information to physicians and health care professionals. It is used to support clinical

decision making by providing rapid, science-based answers to questions about the diagnosis, treatment, prognosis, and management of various medical conditions. Invited by Prof. Barbara Turner, Professor of Clinical Medicine and Deputy Editor for DynaMedex, Keck School of Medicine, University of Southern California (USA).

03-10-2024 to 05-04-2025.

22. Member of the Scientific Committee, Lecturer and Organizer of the "Postgraduate Course: Level 1 Autism Spectrum Disorders in Adults – I cycle". The Specialization Course is organized in collaboration with AULSS 9 and financed by the Veneto Region - Project "The Care of Individuals with Autism Spectrum Disorder" - Fund for the Care of Individuals with Autism Spectrum Disorder (DGR 332/2023 and 333/2023).

24-01-2024 to 24-01-2024.

23. Member of the Scientific Committee, Lecturer and Organizer of the "Postgraduate Course: Level 1 Autism Spectrum Disorders in Adults – II cycle". The Specialization Course is organized in collaboration with AULSS 9 and financed by the Veneto Region - Project "The Care of Individuals with Autism Spectrum Disorder" - Fund for the Care of Individuals with Autism Spectrum Disorder (DGR 332/2023 and 333/2023).

26-9-2025 to 21-2-2026.

## Scientific publications

### Peer-reviewed scientific articles published in international journals

1. Cuijpers P, Harrer M, Miguel C, Karyotaki E, **Papola D**. Does baseline severity interact with the effects of psychotherapy for depression? A meta-analytic review. *J Affect Disord* 2026;121106.
2. Zaccoletti D, Mosconi C, Gastaldon C, Benedetti L, Gottardi C, **Papola D**, Ponzi O, Purgato M, Naudet F, Cristea IA, Barbui C, Ostuzzi G. Comparison of antidepressant deprescribing strategies in individuals with clinically remitted depression: a systematic review and network meta-analysis. *Lancet Psy* 2026;13(1):24-36.
3. Purgato M, Albanese E, Gross AL, Annoni AM, Acarturk C, Cadorin C, Jordans MJD, Lund C, **Papola D**, Prina E, Sijbrandij M, Silva M, Tedeschi F, Tol WA, Barbui C. How to distinguish promotion, prevention, and treatment trials in public mental health: development and validation of the VErona-LUGano Tool (VELUT). *Epidemiol Psychiatr Sci* 2025;34:e54.
4. Harrer M, Miguel C, Tong L, Kuper P, Sprenger AA, Furukawa Y, Wang Y, van Ballegooijen W, Ciharova M, Panagiotopoulou OM, Cristea I, Hamblen JL, Schnurr PP, Riper H, Sijbrandij M, Karyotaki E, van Straten A, Furukawa TA, **Papola D**, Leucht S, Cuijpers P. Effectiveness of digital interventions for eight mental disorders: A meta-analytic synthesis. *Internet interv* 2025;41:100860.
5. Pinucci I, Tedeschi F, Serra R, Patanè M, Acartürk C, Andriani D, Bryant RA, Burchert S, Caggiu S, Campos D, Conflitti C, Davis-Paturet C, Felez-Nobrega M, Fuhr D, Hall BJ, Haro JM, Huizink AC, Knaevelsrud C, Kurt G, Lam A, Leijen I, Mediavilla R, Melchior M, Mittendorfer-Rutz E, Morina N, Monzio Compagnoni M, Nicaise P, Palantza C, Panter-Brick C, **Papola D**, Quero S, Rodriguez Prada C, Seedat S, Setyowibowo H, Smith P, van der Waerden J, Walter H, Witteveen A, Pasquini M, Sijbrandij M, Barbui C, Tarsitani L. Resilient outcomes in people with a history of mental disorder during the COVID-19 pandemic: an international 2-years longitudinal prospective study. *Soc Psychiatry Psychiatr Epidemiol* 2025.
6. Jiménez-Orenga N, Miguel C, González-Robles A, Fernández-Álvarez J, Grimaldos J, Bretón-López J, Botella C, Cuijpers P, García-Palacios A, **Papola D**, Quero S, Riper H, Díaz-García A. Transdiagnostic psychological interventions for emotional disorders: A comprehensive meta-analysis. *J Affect Disord* 2025;388:119537.
7. Harrer M, Miguel C, van Ballegooijen W, Ciharova M, Plessen CY, Kuper P, Sprenger AA, Buntrock C, **Papola D**, Cristea IA, de Ponti N, Bašić Đ, Pauley D, Driessen E, Quero S, Grimaldos J, Buendía SF, Botella C, Hamblen JL, Schnurr PP, Larsen SE, Pfund RA, Motrico E, Gómez-Gómez I, Setkowski K, Matbouriahi M, Wang Y, Rawee J, Riper H,

van Straten A, Sijbrandij M, Leucht S, Furukawa TA, Karyotaki E, Cuijpers P. Effectiveness of psychotherapy: Synthesis of a "meta-analytic research domain" across world regions and 12 mental health problems. *Psychol Bull* 2025;151(5):600-667.

8. Kip A, Ritter L, Hoppen TH, **Papola D**, Ostuzzi G, Barbui C, Morina N. Psychological interventions for adult posttraumatic stress disorder: A systematic review of published meta-analyses. *J Anxiety Disord* 2025;112:103017.
9. Cuijpers P, Harrer M, Miguel C, Ciharova M, **Papola D**, Basic D, Botella C, Cristea I, de Ponti N, Donker T, Driessen E, Franco P, Gómez-Gómez I, Hamblen J, Jiménez-Orenga N, Karyotaki E, Keshen A, Linardon J, Motrico E, Matbouriahi M, Panagiotopoulou OM, Pfund RA, Plessen CY, Riper H, Schnurr PP, Sijbrandij M, Toffolo MBJ, Tong L, van Ballegooijen W, van der Ven E, van Straten A, Wang Y, Furukawa TA. Cognitive Behavior Therapy for Mental Disorders in Adults: A Unified Series of Meta-Analyses. *JAMA Psychiatry* 2025:e250482.
10. De Luca B, Canozzi A, Mosconi C, Gastaldon C, **Papola D**, Metelli A, Tedeschi F, Amaddeo F, Purgato M, Solmi M, Barbui C, Vita G, Ostuzzi G. Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis. *Br J Psychiatry* 2025;227(2):553-66.
11. **Papola D**, Patel V. Towards person-centered care in global mental health: implications for meta-analyses and clinical trials. *Epidemiol Psychiatr Sci* 2025;34:e13.
12. Turrini G, Purgato M, Cadorin C, Bartucz M, Cristofalo D, Gastaldon C, Nosè M, Ostuzzi G, **Papola D**, Prina E, Tedeschi F, Witteveen AB, Sijbrandij M, Barbui C. Comparative efficacy and acceptability of psychosocial interventions for PTSD, depression, and anxiety in asylum seekers, refugees, and other migrant populations: a systematic review and network meta-analysis of randomised controlled studies. *Lancet Reg. Health Eur* 2025;48:101152.
13. Ang L, Lee MS, Song E, Lee HW, Cao L, Zhang J, Wang Q, Jung J, Jang S, Gastaldon C, Reynolds CF, Cuijpers P, Patel V, Barbui C, Yao L, **Papola D**. Psychotherapeutic treatments for depression in older adults. *Cochrane Database Syst Rev* 2024;11(11):CD015976.
14. Wright S, Karyotaki E, Cuijpers P, Bisson J, **Papola D**, Witteveen AB, Back SE, Bichescu-Burian D, Capezzani L, Cloitre M, Devilly GJ, Elbert T, Mello M, Ford JD, Grasso D, Gamito P, Gray R, Haller M, Hunt N, Kleber RJ, König J, Kullack C, Laugharne J, Liebman R, Lee CW, Lely J, Markowitz JC, Monson C, Nijdam MJ, Norman SB, Olff M, Orang TM, Ostacoli L, Paunovic N, Petkova E, Resick P, Rosner R, Schauer M, Schmitz JM, Schnyder U, Smith BN, Vujanovic AA, Zang Y, Duran ÉP, Neto FL, Seedat S, Sijbrandij M. Predictors of study dropout in cognitive-behavioural

therapy with a trauma focus for post-traumatic stress disorder in adults: An individual participant data meta-analysis. *BMJ Ment Health* 2024;27(1):e301159.

15. Eugene D, Nöthling J, Tarsitani L, Palantza C, **Papola D**, Barbui C, Bryant R, Panter-Brick C, Hall BJ, Lam AIF, Huizink AC, Fuhr D, Purba FD, Mittendorfer-Rutz E, Andriani D, van der Waerden J, Acartürk C, Kurt G, Burchert S, Knaevelsrud C, Witteveen AB, Patane M, Quero S, Díaz-García A, Morina N, Pinucci I, Sijbrandij M, Seedat S. Mental health during the Covid-19 pandemic: An international comparison of gender-related home and work-related responsibilities, and social support. *Arch Womens Ment Health* 2024.
16. Vita G, Pollini D, Canozzi A, **Papola D**, Gastaldon C, Correll CU, Barbui C, Ostuzzi G. Efficacy and acceptability of long-acting antipsychotics in acutely ill individuals with schizophrenia-spectrum disorders: A systematic review and network meta-analysis. *Psychiatry Res* 2024;340:116124.
17. Purgato M, Albanese E, **Papola D**, Prina E, Tedeschi F, Gross A, Sijbrandij M, Acarturk C, Annoni AM, Silva M, Jordans MJD, Lund C, Tol WA, Cuijpers P, Barbui C. How to distinguish promotion, prevention and treatment trials in public mental health? Study protocol for the development of the VErona-LUgano Tool (VELUT). *BMJ Open* 2024;14(8):e082652.
18. de Ponti N, Matbouriahi M, Franco P, Harrer M, Miguel C, **Papola D**, Sicimoğlu A, Cuijpers P, Karyotaki E. The efficacy of psychotherapy for social anxiety disorder, a systematic review and meta-analysis. *J Anxiety Dis* 2024;104,102881.
19. **Papola D**, Prina E, Ceccarelli C, Cadorin C, Gastaldon C, Ferreira MC, Tol WA, van Ommeren M, Barbui C, Purgato M. Psychological and social interventions for the promotion of mental health in people living in low- and middle-income countries affected by humanitarian crises. *Cochrane Database Syst Rev* 2024;21;5:CD014300.
20. Cuijpers P, Miguel C, Ciharova M, Harrer M, Basic D, Cristea IA, de Ponti N, Driessens E, Hamblen J, Larsen SE, Matbouriahi M, **Papola D**, Pauley D, Plessen CY, Pfund RA, Setkowski K, Schnurr PP, van Ballegooijen W, Wang Y, Riper H, van Straten A, Sijbrandij M, Furukawa TA, Karyotaki E. Absolute and relative outcomes of psychotherapies for eight mental disorders: a systematic review and meta-analysis. *World Psychiatry* 2024;23(2):267-75.
21. Cadorin C, Purgato M, Turrini G, Prina P, Cabral Ferreira M, Cristofalo C, Bartucz MB, Witteveen AB, Sijbrandij M, **Papola D**, Barbui C. Mapping the evidence on psychosocial interventions for migrant populations: Descriptive analysis of a living database of randomized studies. *Glob Ment Health (Camb)* 2024;11:e35.

22. Ostuzzi G, Gastaldon C, Tettamanti M, Cartabia M, Monti I, Aguglia A, Aguglia E, Bartoli F, Callegari C, Canozzi A, Carbone EA, Carrà G, Caruso R, Cavallotti S, Chiappini S, Colasante F, Compri B, D'Agostino A, De Fazio P, de Filippis R, Gari M, Ielmini M, Ingrosso G, Mammarella S, Martinotti G, Rodolico A, Roncone R, Sterzi E, Tarsitani L, Tiberto E, Todini L, Amaddeo F, D'Avanzo B; **VESPA Study Group**; Barbato A, Barbui C. Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial. *EClinicalMedicine* 2024;69:102491.
23. Barbui C, **Papola D**, Todesco B, Gastaldon C, Ostuzzi G. Ground-breaking change to the mental health section of the WHO Model List of Essential Medicines: implications for low- and middle-income countries. *Epidemiol Psychiatr Sci* 2024; 33,e3,1-6.
24. Wright SL, Karyotaki E, Cuijpers P, Bisson J, **Papola D**, Witteveen A, Suliman S, Spies G, Ahmadi K, Capezzani L, Carletto S, Karatzias T, Kullack C, Laugharne J, Lee CW, Nijdam MJ, Olff M, Ostacoli L, Seedat S, Sijbrandij M. EMDR v. other psychological therapies for PTSD: a systematic review and individual participant data meta-analysis. *Psychol Med* 2024;4:1-9.
25. **Papola D**, Barbui C, Patel V. Leave no one behind: Rethinking policy and practice at the national level to prevent mental disorders. *Ment Health Prev* 2024; 33, 200317.
26. Li G, Li Y, Fong Lam AJ, Tang W, Seedat S, Barbui C, **Papola D**, Panter-Brick C, van der Waerden J, Bryant R, Mittendorfer-Rutz E, Gémes K, Purba FD, Setyowibowo H, Pinucci I, Palantza C, Acarturk C, Kurt G, Tarsitani L, Morina N, Burchert S, Patanè M, Quero S, Campos D, Huijink AC, Fuhr DC, Spiller T, Sijbrandij M, Hall BJ. Understanding the protective effect of social support on depression symptomatology from a longitudinal network perspective. *BMJ Ment Health* 2023;26(1):e300802
27. **Papola D**, Karyotaki E, Purgato M, Sijbrandij M, Tedeschi F, Cuijpers P, Efthimiou O, Furukawa TA, Patel V, Barbui C. Dismantling and personalizing task-sharing psychosocial interventions for common mental disorders: a study protocol for an individual participant data component network meta-analysis. *BMJ-Open* 2023;13:e077037.
28. Purgato M, Prina E, Ceccarelli C, Cadorin C, Abdulmalik JO, Amaddeo F, Arcari L, Churchill R, Jordans MJ, Lund C, **Papola D**, Uphoff E, van Ginneken N, Tol WA, Barbui C. Primary-level and community worker interventions for the prevention of mental disorders and the promotion of well-being in low- and middle-income countries. *Cochrane Database Syst Rev* 2023;10(10):CD014722.

29. **Papola D**, Miguel C, Mazzaglia M, Franco P, Tedeschi F, Romero SA, Patel AR, Ostuzzi G, Gastaldon C, Karyotaki E, Harrer M, Purgato P, Sijbrandij M, Patel V, Furukawa TA, Cuijpers P, Barbui C. Psychotherapies for generalized anxiety disorders in adults: systematic review and network meta-analysis of randomized-controlled trials. *Jama Psy* 2023; e233971.
30. **Papola D**, Ostuzzi G, Gastaldon C, Barbui C. The WHO Model List of Essential Medicines for Children needs its own identity: the case of psychotropic medicines. *Lancet Child Adolesc* 2023; S2352-4642(23)00220-1.
31. **Papola D**, Ostuzzi G, Todesco B, Gastaldon C, Hanna F, Chatterjee S, van Ommeren M, Barbui C. Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders. *Lancet Psychiatry* 2023; 10(10):809-816
32. Baldini V, Di Stefano R, Rindi LV, Ahmed AO, Koola MM, Solmi M, **Papola D**, De Ronchi D, Barbui C, Ostuzzi G. Association between adverse childhood experiences and suicidal behavior in schizophrenia spectrum disorders: a systematic review and meta-analysis. *Psychiatry Res* 2023; 115488.
33. Marotta A, Lasalvia A, Fiorio M, Zanalda E, Di Sciascio G, Palumbo C, **Papola D**, Barbui C, Tinazzi M. Psychiatrists' attitudes towards functional neurological disorders: results from a national survey. *Front Psychiatry* 2023; 14:1216756
34. Prina E, Ceccarelli C, Abdulmalik JO, Amaddeo F, Cadorin C, **Papola D**, Tol WA, Lund C, Barbui C, Purgato M. Task-sharing psychosocial interventions for the prevention of common mental disorders in the perinatal period in low- and middle-income countries: A systematic review and meta-analysis. *Int J Soc Psychiatry* 2023; 207640231174451.
35. Cuijpers P, Miguel C, Harrer M, Plessen CY, Ciharova M, **Papola D**, Ebert D, Karyotaki E. Psychological treatment of depression: A systematic overview of a 'Meta-Analytic Research Domain'. *J Affect Disord* 2023; 335:141-51.
36. Ostuzzi G, Tedeschi F, Bertolini F, Cotugno C, Aguglia A, Bartoli F, Carrà G, D'Agostino A, Martinotti G, Barbui C, Gastaldon C, **Papola D**. Clinical trajectories of individuals with severe mental illness continuing and discontinuing long-acting antipsychotics: a one-year mirror-image analysis from the STAR Network Depot study. *Schizophrenia* 2023; 9:23.
37. Hirt J, Schönenberger CM, Ewald H, Lawson DO, **Papola D**, Rohner R, Suter K, Lin S, Germini F, Zeng L, Shahabinezhad A, Chowdhury SF, Gao Y, Bhattacharjee A, Lima JP, Marusic A, Buljan I, Agarwal A, Guyatt GH, Briel M, Schandelmaier S. Introducing the Library of Guidance for Health Scientists (LIGHTS): A Living Database for Methods Guidance. *JAMA Netw Open* 2023;6(2):e2253198.

38. Todesco B, Ostuzzi G, Gastaldon C, **Papola D**, Barbui C. Essential medicines for mental disorders: comparison of 121 national lists with WHO recommendations. *Arch Public Health* 2023;81(1):8.
39. Ritunnano R, **Papola D**, Broome MR, Nelson B. Phenomenology as a resource for translational research in mental health: methodological trends, challenges and new directions. *Epidemiol Psychiatr Sci* 2023;32:e5.
40. Kip A, Iseke LN, **Papola D**, Gastaldon C, Barbui C, Morina N. Efficacy of psychological interventions for PTSD in distinct populations - An evidence map of meta-analyses using the umbrella review methodology. *Clin Psychol Rev* 2022; 102239.
41. **Papola D**, Ostuzzi G, Tedeschi F, Gastaldon C, Purgato M, Del Giovane C, Pompili A, Pauley D, Karyotaki E, Sijbrandij M, Furukawa TA, Cuijpers C, Barbui C. CBT treatment delivery formats for panic disorder: a systematic review and network meta-analysis of randomized controlled trials. *Psychol Med* 2023;53,614-24.
42. Gastaldon C, Schoretsanitis G, Arzenton E, Raschi E, **Papola D**, Ostuzzi G, Moretti U, Seifritz E, Kane JM, Trifirò G, Barbui C. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database. *Drug Saf* 2022; 45(12):1539-49.
43. Tarsitani L, Pinucci I, Tedeschi F, Patanè M, **Papola D**, Palantza C, Acarturk C, Björkenstam E, Bryant R, Burchert S, Davisse-Paturet C, Díaz-García A, Farrel R, Fuhr DC, Hall BJ, Huizink AC, Lok Fong Lam A, Kurt G, Leijen I, Mittendorfer-Rutz E, Morina N, Panter-Brick C, Dermawan Purba F, Quero S, Seedat S, Setyowibowo H, van der Waerden J, Pasquini M, Sijbrandij M, Barbui C. Resilience of people with chronic medical conditions during the COVID-19 pandemic: a 1-year longitudinal prospective survey. *BMC Psychiatry* 2022; 22:633.
44. Gastaldon C, Arzenton E, Raschi E, Spigset O, **Papola D**, Ostuzzi G, Moretti U, Trifirò G, Barbui C, Schoretsanitis G. Neonatal withdrawal syndrome following in utero exposure to antidepressants: A disproportionality analysis of VigiBase, the WHO spontaneous reporting database. *Psychol Med* 2022, 1-9.
45. Feller D, Fox I, Gozzer P, Trentin F, **Papola D**. Exercise for depressive symptoms in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. *Arch Phys Med Rehabil* 2022; 25:S0003-9993(22)00594-9.
46. Cuijpers P, Miguel C, **Papola D**, Harrer M, Karyotaki E. From living systematic reviews to meta-analytical research domains. *Evid Based Ment Health* 2022; ebmental-2022-300509.

47. D'Agostino A, Aguglia A, Barbui C, Bartoli F, Carrà G, Cavallotti S, Chirico M, Ostinelli EG, Zangani C, Martinotti G, Ostuzzi G; **STAR Network Depot Investigators**. Off-label long acting injectable antipsychotics in real-world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study. *BMC Psychiatry* 2022;22(1):442.
48. Ostuzzi G, Vita G, Bertolini F, Tedeschi F, De Luca B, Gastaldon C, Nosé M, **Papola D**, Purgato M, Del Giovane C, Correll CU, Barbui C. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis. *Lancet Psychiatry* 2022;23:S2215-0366(22)00158-4.
49. Turrini G, Purgato M, Tedeschi F, Acartürk C, Anttila M, Au T, Carswell K, Churchill R, Cuijpers P, Friedrich F, Gastaldon C, Klein T, Kösters M, Lantta T, Nosè M, Ostuzzi G, **Papola D**, Popa M, Sijbrandij M, Tarsitani L, Todini L, Uygun E, Välimäki M, Walker L, Wancata J, White RG, Zanini E, van Ommeren M, Barbui C. Long-term effectiveness of Self-Help Plus in refugees and asylum seekers resettled in Western Europe: 12-month outcomes of a randomised controlled trial. *Epidemiol Psychiatr Sci* 2022;8:31:e39.
50. Gémes K, Bergström J, **Papola D**, Barbui C, Lam AIF, Hall BJ, Seedat S, Morina N, Quero S, Campos D, Pinucci I, Tarsitani L, Deguen S, van der Waerden J, Patanè M, Sijbrandij M, Acartürk C, Burchert S, Bryant RA, Mittendorfer-Rutz E. Symptoms of anxiety and depression during the COVID-19 pandemic in six European countries and Australia - Differences by prior mental disorders and migration status. *J Affect Disord* 2022;19:S0165-0327(22)00596-1.
51. Ostuzzi G, Gastaldon C, **Papola D**, Barbui C. Calling for policy actions to increase access to long-acting antipsychotics in low-income and middle-income countries. *Epidemiol Psychiatr Sci* 2022;31:e34.
52. Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, del Fabro L, Gastaldon C, **Papola D**, Purgato M, Nosari G, Del Giovane C, Correll CU, Barbui C. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. *World Psychiatry* 2022;21(2):295-307.
53. **Papola D**, Prina E, Ceccarelli C, Gastaldon C, Tol WA, van Ommeren M, Barbui C, Purgato M. Psychological and social interventions for the promotion of mental health in people living in low- and middle-income countries affected by humanitarian crises (protocol). *Cochrane Database Syst Rev* 2022;(4):CD014300.

54. Wright SL, Karyotaki E, Bisson JI, Cuijpers P, **Papola D**, Witteveen AB, Seedat S, Sijbrandij M. Protocol for individual participant data meta-analysis of interventions for post-traumatic stress. *BMJ Open* 2022;12(2):e054830
55. Aguglia A, Fusar-Poli L, Amerio A, Placenti V, Concerto C, Martinotti G, Carrà G, Bartoli F, D'Agostino A, Serafini G, Amore M, Aguglia E, Ostuzzi G, Barbui C; **STAR Network Investigators**. The Role of Attitudes Toward Medication and Treatment Adherence in the Clinical Response to LAIs: Findings From the STAR Network Depot Study. *Front Psychiatry* 2021;12:784366.
56. Gastaldon C, Laurenzi PF, Schoretsanitis G, **Papola D**, Cristea IA, Naudet F, Ostuzzi G, Barbui C. Esketamine for treatment-resistant depression in adults (Protocol). *Cochrane Database Syst Rev* 2022;(1):CD015071.
57. **Papola D**, Ostuzzi G, Tedeschi F, Gastaldon C, Purgato M, Del Giovane C, Pompili A, Pauley D, Karyotaki E, Sijbrandij M, Furukawa TA, Cuijpers C, Barbui C. Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomized controlled trials. *Br J Psychiatry* 2022;221(3):507-519.
58. Purgato M, Carswell K, Tedeschi F, Acarturk C, Anttila M, Au T, Bajbouj M, Baumgartner J, Biondi M, Churchill R, Cuijpers P, Koesters M, Gastaldon C, Ilkkursun Z, Lantta T, Nosè M, Ostuzzi G, **Papola D**, Popa M, Roselli V, Sijbrandij M, Tarsitani L, Turrini G, Välimäki M, Walker L, Wancata J, Zanini E, White R, van Ommeren M, Barbui C. Effectiveness of Self-Help Plus in Preventing Mental Disorders in Refugees and Asylum Seekers in Western Europe: A Multinational Randomized Controlled Trial. *Psychother Psychosom* 2021;20:1-12.
59. Bertolini F, Ostuzzi G, Pievani M, Aguglia A, Bartoli F, Bortolaso P, Callegari C, Caroleo M, Carrà G, Corbo M, D'Agostino A, De Fazio P, Magliocco F, Martinotti G, Ostinelli EG, Piccinelli MP, Tedeschi F, Barbui C; **STAR Network Investigators**. Comparing Long-Acting Antipsychotic Discontinuation Rates Under Ordinary Clinical Circumstances: A Survival Analysis from an Observational, Pragmatic Study. *CNS Drugs* 2021;35(6):655-665.
60. Pauley D, Cuijpers P, **Papola D**, Miguel C, Karyotaki E. Two decades of digital interventions for anxiety disorders: A systematic review and meta-analysis of treatment effectiveness. *Psychol Med* 2021; 1-13.
61. Purgato M, Abdulmalik JO, Prina E, Ceccarelli C, Tol WA, van Ginneken N, Uphoff E, **Papola D**, Amaddeo F, Churchill R, Jordans MJD, Lund C, Barbui C. Primary-level and community worker interventions for the prevention of mental disorders and the

promotion of well-being in low- and middle-income countries (Protocol). *Cochrane Database Syst Rev* 2021;(3):CD014722.

62. Ostuzzi G, Bertolini F, Del Giovane C, Tedeschi F, Bovo C, Gastaldon C, Nosé M, Ogheri F, **Papola D**, Purgato M, Turrini G, Correll CU, Barbui C. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. *Am J Psychiatry* 2021;178(5):424-436.
63. Barbui C, Bertolini F, Bartoli F, Calandra C, Callegari C, Carrà G, D'Agostino A, Lucii C, Martinotti G, Mastromo D, Moretti D, Monzani E, Porcellana M, Prestia D, Ostuzzi G; **STAR Network Investigators**. Reasons for initiating long-acting antipsychotics in psychiatric practice: findings from the STAR Network Depot Study. *Ther Adv Psychopharmacol* 2020;10:2045125320978102
64. **Papola D**, Ostuzzi G, Gastaldon C, Purgato M, del Giovane C, Pompili A, Karyotaki E, Sijbrandij M, Furukawa TA, Cuijpers P, Barbui C. Which psychotherapy is effective in panic disorder? And which delivery formats are supported by the evidence? Study protocol for two systematic reviews and network meta-analyses. *BMJ Open* 2020;10:e038909.
65. **Papola D**, Purgato M, Gastaldon C, Bovo C, van Ommeren M, Barbui C, Tol WA. Psychological and social interventions for the prevention of mental disorders in people living in low- and middle-income countries affected by humanitarian crises. *Cochrane Database Syst Rev* 2020;(9):CD012417.
66. Bartoli F, Ostuzzi G, Crocamo C, Corbo M, D'Agostino A, Martinotti G, Ostinelli EG, Tabacchi T, Barbui C, Carrà G, **STAR Network Depot Investigators**. Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: findings from the STAR Network Depot Study. *Int Clin Psychopharmacol* 2020;35(4):214-220.
67. Ostuzzi G, Gastaldon C, Barbato A, D'Avanzo B, Tettamanti M, Monti I, Aguglia A, Aguglia E, Alessi MC, Amore M, Bartoli F, Biondi M, Bortolaso P, Callegari C, Carrà G, Caruso R, Cavallotti S, Crocamo C, D'Agostino A, De Fazio P, Di Natale C, Giusti L, Grassi L, Martinotti G, Nosé M, **Papola D**, Purgato M, Rodolico A, Roncone R, Tarsitani L, Turrini G, Zanini E, Amaddeo F, Ruggeri M, Barbui C. Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial. *Trials* 2020;21(1):695.
68. Ostuzzi G, Gastaldon C, **Papola D**, Fagiolini A, Dursun S, Taylor D, Correll CU, Barbui C. Pharmacological treatment of hyperactive delirium in people with COVID-19:

rethinking conventional approaches. *Ther Adv Psychopharmacol* 2020;10:2045125320942703.

69. Ostuzzi G, **Papola D**, Gastaldon C, Schoretsanitis G, Bertolini F, Amaddeo F, Cuomo A, Emsley R, Fagiolini A, Imperadore G, Kishimoto T, Michencigh G, Nosé M, Purgato M, Dursun S, Stubbs B, Taylor D, Thornicroft G, Ward PB, Hiemke C, Correll CU, Barbui C. Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. *BMC Med* 2020;18(1):215.
70. Gastaldon C, **Papola D**, Ostuzzi G, Barbui C. Esketamine clinical trials: reply to Maju et al. *Epidemiol Psychiatr Sci* 2020;29:e122.
71. Morgano GP, Fulceri F, Nardocci F, Barbui C, Ostuzzi G, **Papola D**, Fatta LM, Faucci A, Coclite D, Napoletano A, De Crescenzo F, D'Alo GL, Amato L, Cinquini M, Iannone P, Schunemann HJ, Scattoni ML, on behalf of the Italian National Institute of Health guideline working group on Autism Spectrum Disorder. Introduction and methods of the evidence-based guidelines for the diagnosis and management of autism spectrum disorder by the Italian National Institute of Health. *Health Qual Life Outcomes* 2020;18(1):81.
72. Barbui C, Purgato M, Abdulmalik J, Acarturk C, Eaton J, Gastaldon C, Gureje O, Hanlon C, Jordans M, Lund C, Nose M, Ostuzzi G, **Papola D**, Tedeschi F, Tol W, Turrini G, Patel V, Thornicroft G. Efficacy of psychosocial interventions for mental health outcomes in low-income and middle-income countries: an umbrella review. *Lancet Psychiatry* 2020;7(2):162-72.
73. Gastaldon C, **Papola D**, Ostuzzi G, Barbui C. Esketamine for treatment resistant depression: a trick of smoke and mirrors? *Epidemiol Psychiatric Sci* 2020;29:e79.
74. Cuijpers P, Quero S, **Papola D**, Cristea IA, Karyotaki E. Care-as-usual control groups across different settings in randomized trials on psychotherapy for adult depression: a meta-analysis. *Psychol Med* 2019;1-11.
75. Purgato M, Tedeschi F, Betancourt TS, Bolton P, Bonetto C, Gastaldon C, Gordon J, O'Callaghan P, **Papola D**, Peltonen K, Punamaki RL, Richards J, Staples JK, Unterhitzenberger J, de Jong J, Jordans MJD, Gross AL, Tol WA, Barbui C. Mediators of focused psychosocial interventions for children in low-resource humanitarian settings: analysis from an Individual Participant Dataset with 3,143 participants. *J Child Psychol Psychiatry* 2019;61(5):584-93.
76. Tsujimoto Y, Tsutsumi Y, Kataoka Y, Tsujimoto H, Yamamoto Y, **Papola D**, Guyatt GH, Fukuhara S, Furukawa TA. Statistical significance did not affect time to publication in non-Cochrane systematic reviews: a meta epidemiological study. *J Clin Epidemiol* 2019;115:25-34.

77. **Papola D**, Ostuzzi G, Gastaldon C, Morgano GP, Dragioti E, Carvalho AF, Fusar-Poli P, Correll CU, Solmi M, Barbui C. Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies. *Acta Psychiatr Scand* 2019;140(3):227-43.
78. Purgato M, Carswell K, Acarturk C, Au T, Akbai S, Anttila M, Baumgartner J, Bailey D, Biondi M, Bird M, Churchill R, Eskici S, Hansen LJ, Heron P, Ilkkursun Z, Kilian R, Koesters M, Lantta T, Nose M, Ostuzzi G, **Papola D**, Popa M, Sijbrandij M, Tarsitani L, Tedeschi F, Turrini G, Uygun E, Valimaki MA, Wancata J, White R, Zanini E, Cuijpers P, Barbui C, Van Ommeren M. Effectiveness and cost-effectiveness of Self-Help Plus (SH+) for preventing mental disorders in refugees and asylum seekers in Europe and Turkey: study protocols for two randomised controlled trials. *BMJ Open* 2019;9(5):e030259.
79. Ostuzzi G, Turrini G, Gastaldon C, **Papola D**, Rayner L, Caruso R, Grassi L, Hotopf M, Barbui C. Efficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysis. *Int Clin Psychopharmacol* 2019;34(2):65-75.
80. Barbui C, **Papola D**, Saraceno B. The Italian mental health-care reform: public health lessons. *Bull World Health Organ* 2018;96(11):731-731A.
81. Ostuzzi G, Mazzi MA, Terlizzi S, Bertolini F, Aguglia A, Bartoli F, Bortolaso P, Callegari C, Caroleo M, Carra G, Corbo M, D'Agostino A, Gastaldon C, Lucii C, Magliocco F, Martinotti G, Nose M, Ostinelli EG, **Papola D**, Piccinelli M, Piccoli A, Purgato M, Tabacchi T, Turrini G, Ruggeri M, Barbui C and the STAR Network Investigators. Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy. *PLoS One* 2018;13(8):e0201371.
82. Barbui C, **Papola D**, Saraceno B. Forty years without mental hospitals in Italy. *Int J Ment Health Syst* 2018;12:43.
83. Purgato M, Gastaldon C, **Papola D**, van Ommeren M, Barbui C, Tol WA. Psychological therapies for the treatment of mental disorders in low- and middle-income countries affected by humanitarian crises. *Cochrane Database Syst Rev* 2018;7(7):CD011849.
84. **Papola D**, Ostuzzi G, Thabane L, Guyatt GH, Barbui C. Antipsychotic drug exposure and risk of fracture: a systematic review and meta-analysis of observational studies. *Int Clin Psychopharmacol* 2018;33(4):181-96.
85. Purgato M, Gross AL, Betancourt T, Bolton P, Bonetto C, Gastaldon C, Gordon J, O'Callaghan P, **Papola D**, Peltonen K, Punamaki RL, Richards J, Staples JK, Unterhitzenberger J, van Ommeren M, de Jong J, Jordans MJD, Tol WA, Barbui C.

Focused psychosocial interventions for children in low resource humanitarian settings: a systematic review and individual participant data meta-analysis. *Lancet Glob Health* 2018;6(4):e390-e400.

86. **Papola D**, Gastaldon C, Ostuzzi G. Can a digital medicine system improve adherence to antipsychotic treatment? *Epidemiol Psychiatr Sci* 2018;27(3):227-29.
87. Tsujimoto Y, Tsutsumi Y, Kataoka Y, Tsujimoto H, Yamamoto Y, **Papola D**, Guyatt GH, Fukuhara S, Furukawa T. Association between statistical significance and time to publication among systematic reviews: a study protocol for a meta-epidemiological investigation. *BMJ Open* 2017;7(10):e018856.
88. Sadeghirad B, Siemieniuk RAC, Brignardello-Petersen R, **Papola D**, Lytvyn L, Vandvik PO, Merglen A, Guyatt GH, Agoritsas T. Corticosteroids for treatment of sore throat: systematic review and meta-analysis of randomised trials. *BMJ* 2017;358:j3887.
89. Gastaldon C, **Papola D**, Ostuzzi G. Antipsychotic combinations in schizophrenia. *Epidemiol Psychiatr Sci* 2017;26(5):462-5.
90. Barbui C, Gastaldon C, **Papola D**, Ostuzzi G. Antipsychotic drug exposure and risk of myocardial infarction. *Epidemiol Psychiatr Sci* 2017;26(1):18-21.
91. Ostuzzi G, **Papola D**, Gastaldon C, Barbui C. New EMA report on paliperidone 3-month injections: taking clinical and policy decision without an adequate evidence base. *Epidemiol Psychiatr Sci* 2017;26(3):231-3.
92. Purgato M, Gastaldon C, **Papola D**, van Ommeren M, Barbui C, Tol WA; Psychological and social interventions for the prevention of mental disorders in people living in low- and middle-income countries affected by humanitarian crises (study protocol). *Cochrane Database Syst Rev* 2016;(11):CD012417
93. Carra G, Crocamo C, Bartoli F, Lax A, Tremolada M, Lucii C, Martinotti G, Nose M, Bighelli I, Ostuzzi G, Castellazzi M, Clerici M, Barbui C; **The STAR Network Group**. First-generation antipsychotics and QTc: any role for mediating variables? *Hum Psychopharmacol* 2016;31(4):313-8.
94. Barbui C, Bighelli I, Carra G, Castellazzi M, Lucii C, Martinotti G, Nose M, Ostuzzi G; **The STAR Network Group**. Antipsychotic dose mediates the association between polypharmacy and corrected QT interval. *PLoS One* 2016;11(2):0148212.
95. Purgato M, Gastaldon C, **Papola D**, van Ommeren M, Barbui C, Tol WA. Psychological therapies for the treatment of mental disorders in low- and middle-income countries affected by humanitarian crises (study protocol). *Cochrane Database Syst Rev* 2015;(10):CD011849.

96. Purgato M, Gastaldon C, **Papola D**, Magni LR, Rossi G, Barbui C. Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine. *Acta Psychiatr Scand* 2015;131(6):408-16.
97. Purgato M, **Papola D**, Gastaldon C, Trespidi C, Magni LR, Rizzo C, Furukawa TA, Watanabe N, Cipriani A, Barbui C. Paroxetine versus other anti-depressive agents for depression. *Cochrane Database Syst Rev* 2014;(4):CD006531.
98. Magni LR, Purgato M, Gastaldon C, **Papola D**, Furukawa TA, Cipriani A, Barbui C. Fluoxetine versus other types of pharmacotherapy for depression. *Cochrane Database Syst Rev* 2013;(7):CD004185.

Articles in international non-indexed journals

99. Gastaldon C, **Papola D**, Purgato M, Barbui C. Cochrane Global Mental Health: A New Cochrane Network has been Established in Verona. *Global Mental Health & Psychiatry Newsletter*. Newsletter Volume IV, No. 1 January 2018.

Scientific articles Italian national journals

100. Bertelli M, Scuticchio D, Bianco A, Buonaguro EF, Laghi F, Ghelma F, Rossi M, Vannucchi G, Cavagnola R, Chioldelli G, Corti S, Leoni M, Gusso S, Cappa C, Filighera L, Simone S, Zunino M, Belotti R, Perrone F, Di Sarro R, Keller R, Arduino M, Brondino N, Politi P, Boschetto M, Lupi M, Lo Presti E, Pace P, Armellini M, Santambrogio J, Barbui C, **Papola D**, Ceccarani P, Franchini R, Bergamin C, Scattoni ML. Consigli per la gestione dell'epidemia COVID-19 e dei fattori di distress psichico associati per le persone con disabilità intellettiva e autismo con necessità elevata e molto elevata di support. *Giornale Italiano dei Disturbi del Neurosviluppo* 2020;5(1):40-52.
101. Purgato M, Tedeschi F, Prina E, **Papola D**, Gastaldon C, Borghesani A, Barbui C. Come reagiscono al trauma i bambini sfollati? Un'analisi esplorativa degli studi condotti in contesti di guerra [Displaced versus non-displaced children in war contexts: An explorative analysis of psychological reactions to war experiences]. *Quaderni ACP* 2020;27(2):73-7.
102. Purgato M, **Papola D**, Gastaldon C, Barbui C. Interventi psicosociali per bambini che vivono in contesti a basso e medio reddito: Una mappatura delle evidenze scientifiche [Psychosocial interventions for children in low- and middle-income countries: mapping scientific evidence]. *Quaderni ACP* 2019;26(5):208-11;

103. Purgato M, **Papola D**, Gastaldon C, Barbui C. Gli interventi sulla salute mentale della madre e il loro impatto sullo sviluppo del bambino [Interventions on mother mental health and their impact on child development]. *Quaderni ACP* 2016;23(6):255-9.

Book chapters

1. Gottardi C, Gastaldon C, **Papola D**, Barbui C, Ostuzzi G. Trattamenti psicofarmacologici [psychopharmacological treatments]. Book title: Salute Mentale e Dintorni [Mental Health and Related Issues]. Editor: Monzani E. Published: McGraw Hill, 2025 (in press).
2. Ostuzzi G, Gottardi C, **Papola D**, Barbui C, Gastaldon C. Luoghi comuni sulle terapie psicofarmacologiche [Common misconceptions about psychopharmacological therapies]. Book title: Salute Mentale e Dintorni [Mental Health and Related Issues]. Editor: Monzani E. Published: McGraw Hill, 2025 (in press).
3. Ostuzzi G, Gastaldon C, **Papola D**, Barbui C. Promuovere l'uso appropriato degli psicofarmaci [Promoting the rational use of psychiatric drugs]. Book title: La psichiatria sociale in Italia: evidenze ed esperienze [Social psychiatry in Italy: evidence and experiences]. Editor: Fiorillo A. Publisher: Pacini Medicina, 2020.

Posters and abstracts presented at national and international conferences

1. **Papola D**, Patel V, Barbui C. Dismantling task-sharing psychosocial interventions to personalize care for people affected by common mental disorders in poor resource settings. 33<sup>rd</sup> European Congress of Psychiatry; Madrid (Spain), 5-8 April 2025.
2. Hirt J, Chiaborelli M, Schoenenberger C, Ewald H, Lima JP, Glasstetter J, Zegarra RR, Chowdhury SR, Ehrenzeller S, Lin S, **Papola D**, Briel M, Guyatt G, Schandlmaier S. Improving access to methods guidance for clinical guideline developers - the Library of Guidance for Health Scientists (LIGHTS). Guidelines International Network (GIN); Geneva (Switzerland), September 16 – 19, 2025.
3. Somma C, **Papola D**, Todesco B, Ostuzzi G, Gastaldon C, Barbui C. Migliorare l'accesso alle cure del disturbo ossessivo-compulsivo attraverso una revisione della Lista Essenziale dei farmaci dell'Organizzazione Mondiale della Sanità. Congresso Nazionale della Società Italiana di Psichiatria (SIP); Verona (Italy), May 29 – June 1, 2024.
4. Vita G, Pollini D, **Papola D**, Gastaldon C, Correll C, Barbui C, Ostuzzi G. Efficacia e accettabilità degli antipsicotici a lunga durata d'azione negli individui con disturbi dello spettro schizofrenico acutamente sintomatici: una meta-analisi network. Congresso Nazionale della Società Italiana di Psichiatria (SIP); Verona (Italy), May 29 – June 1, 2024.

5. Gastaldon C, **Papola D**, Ostuzzi G, Barbui C. Public Health Psychopharmacology (PHP): the impact of pharmacoepidemiology in public health. 21<sup>st</sup> Biennial Congress of the EPA Section of Epidemiology & Social Psychiatry; Lausanne (Switzerland), 11-14 September 2024.
6. **Papola D**, Patel V, Barbui C. Dismantling task-sharing psychosocial interventions to personalize care for people affected by common mental disorders: developing a taxonomy of active ingredients and ranking their efficacy. 32<sup>nd</sup> European Congress of Psychiatry; Budapest (Hungary), 6-9 April 2024.
7. Marotta A, Fiorio M, Lasalvia A, Nasi ML, Zanalda E, Di Sciascio G, Palumbo C, **Papola D**, Barbui C, Tinazzi M. Opinion, knowledge, and clinical experiences with functional neurological disorders among Italian psychiatrists: results from a national survey. 9th LIMPE-DISMOV ETS Congress; Padova (Italy), 4-6 May 2023.
8. Kip A, Ritter L, Ostuzzi G, **Papola D**, Hoppen TH, Barbui C, Morina N. Psychotherapeutische Interventionen für PTSD bei Erwachsenen: Evidenzübersicht vorhandener Meta-Analysen. 2<sup>nd</sup> Deutscher Psychotherapie Kongress; Berlin (Germany), 10-13 May 2023;
9. Gastaldon C, Schoretsanitis G, Arzenton E, Raschi E, **Papola D**, Ostuzzi G, Moretti U, Seifritz E, Kane JM, Trifirò G, Barbui C. Pharmacovigilance analysis of the Vigibase on antidepressants-related withdrawal syndrome. 31st European Congress of Psychiatry; Paris (France), 25-28 March 2023;
10. Gastaldon C, Arzenton E, Raschi E, Spigset E, **Papola D**, Ostuzzi G, Moretti U, Trifirò G, Barbui C, Schoretsanitis G. Pharmacovigilance analysis of the Vigibase on neonatal withdrawal syndrome following in utero exposure to antidepressants. 31st European Congress of Psychiatry; Paris (France), 25-28 March 2023;
11. Pinucci I, Tarsitani L, Tedeschi F, Patanè M, Serra R, **Papola D**, Palantza C, Acartürk C, Bryant R, Burchert S, Fuhr D, Hall BJ, Mittendorfer- Rutz E, Morina N, Panter-Brick C, Quero S, Seedat S, Setyowibowo H, van der Waerden J, Pasquini M, Sijbrandij M, Barbui C. Resilience of people with a history of mental disorder during the COVID-19 pandemic: a 2-years longitudinal prospective study. 31<sup>st</sup> European Congress of Psychiatry; Paris (France), 25-28 March 2023;
12. Hirt J, Ewald H, Lawson DA, Mbuagbaw L, Rohner R, Schoenenberger C, Germini F, **Papola D**, Zeng L, Suter K, Hemkens LG, Briel M, Schandelmaier S. A systematic survey suggested areas for improving methods guidance and led to the development of a new database. 3<sup>rd</sup> Evidence-Based Research (Evhres) Conference (Online conference), 6-7 October 2022;

13. Schandlmaier S, Hirt J, Ewald H, Rohner R, Schönenberger C, Lawson D, Suter K, Germini F, **Papola D**, Zeng L, Briel M. A new living database for methods guidance. Plenary presentation at the 2022 annual research day of the Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada. 18<sup>th</sup> April 2022.
14. **Papola D**, Karyotaki E, Sijbrandij M, Cuijpers P, Barbui C. Development and regular update of a meta-analytic database of randomized controlled trials: the case of psychological treatments for anxiety disorders. *Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews* 2020;(9 Suppl 1):383 <https://doi.org/10.1002/14651858.CD202001>;
15. Gastaldon C, **Papola D**, Ostuzzi G, Barbui C. Meta-analyses for regulatory purposes: the case of esketamine. *Advances in Evidence Synthesis: special issue. Cochrane Database of Systematic Reviews* 2020;(9 Suppl 1):89 <https://doi.org/10.1002/14651858.CD202001>;
16. Ostuzzi G, Tedeschi F, **Papola D**, Gastaldon C, Purgato M, Del Giovane C, Kolappa K, Echeverri C, Barbui C. Using a network meta-analysis approach to update the WHO Essential Medicines List on long-acting antipsychotics. ENMESH 2019; Lisbon (Portugal), 6-8 June 2019;
17. Tsujimoto Y, Karaoke Y, Tsutsumi Y, Tsujimoto H, **Papola D**. The timing of outcome measurement is not usually defined among systematic review protocols registered in the PROSPERO. 25th Cochrane Colloquium; Edinburgh (Scotland), 16-18 September 2018.
18. Turrini G, Ostuzzi G, Gastaldon C, **Papola D**, Barbui C. Efficacy and acceptability of antidepressants for the treatment of depressive symptoms in adult patients with ischemic heart disease. 6 th Congress of European Association of Psychosomatic Medicine (EAPM); Verona (Italia), 27-30 of June 2018.

Oral presentations at scientific conferences

1. 12/11/2025: “Dismantling task-sharing psychosocial interventions for common mental disorders in resource-poor settings: developing a taxonomy of treatment-specific components and ranking their efficacy at the individual level”. 7<sup>th</sup> Global Mental Health Summit. Cape Town (South Africa) November 10-12, 2025.
2. 12/9/2025: “Dismantling task-sharing psychotherapies for depression and anxiety in resource-poor settings: developing a taxonomy of active ingredients and ranking their efficacy at the individual level”. 19<sup>th</sup> Congress of the International Federation of Psychiatric Epidemiology (IFPE). Trento (Italy) 11-13 September, 2025

3. 20/6/2025: “Affettività negativa, alessitimia ed esiti chirurgici in pazienti sottoposti a chirurgia laparoscopica”. XIV Congresso Nazionale del Gruppo di Ricerca in Psicosomatica (GRP). Verona (Italy) June 19-20, 2025.
4. 20/2/2025: “L’utilizzo del “task-sharing” per l’erogazione di interventi di prevenzione in contesti a basse risorse”. XXIX congresso nazionale SOPS. Roma (Italy) 19-21 February, 2025.
5. 5/7/2024: “Improving access to mental health care through a revision of the who list of essential medicines”. European Network for Mental Health Services Evaluation (ENMESH) conference 2024. Versailles (France) July 4-6, 2024.
6. 5/7/2024: “Personalizing care for people with common mental disorders: a meta-analytic approach”. European Network for Mental Health Services Evaluation (ENMESH) conference 2024. Versailles (France) July 4-6, 2024.
7. 1/6/2024: “La personalizzazione degli interventi psicosociali "task-sharing" nei contesti a basse risorse per la cura delle sindromi ansioso-depressive”. Società Italiana di Psichiatria congress 2024. Verona (Italy).
8. 8/4/2024: “Updating the WHO Model Lists of Essential Medicines to promote global access to the most cost-effective and safe medicines for mental disorders”. 32<sup>nd</sup> European Congress of Psychiatry. Budapest (Hungary).
9. 7/4/2024: “Psychotherapies for generalized anxiety disorder in adults: systematic review and network meta- analysis of randomized-controlled trials”. 32<sup>nd</sup> European Congress of Psychiatry. Budapest (Hungary).
10. 22/2/2024: “Global Mental Health: la salute mentale nel mondo globalizzato”. XXVIII congresso nazionale SOPS. Roma (Italy).
11. 30/10/2023: “Dismantling task-shifting psychosocial interventions to personalize care for people affected by common mental disorders”. The 12th Global Mental Health NIH conference “Research Without Borders”. Bethesda, MD (USA).
12. 5/9/2023: “The regulatory process for drug approval needs independent meta-analytical evidence: is Cochrane a possible candidate? The case of psychotropic medicines.” The 30<sup>th</sup> Cochrane Colloquium 2023, London (UK).
13. 4/9/2023: “Unravelling active ingredients of task-shifting interventions in low-resource settings for common mental disorders: developing a taxonomy of intervention components and ranking their efficacy.” The 30<sup>th</sup> Cochrane Colloquium 2023, London (UK).

14. 10/4/2021: "Which psychotherapy is effective in panic disorder? Findings and reflections from a systematic network meta-analysis." The 29<sup>th</sup> European Congress of Psychiatry – EPA Virtual 2021.
15. 6/9/2019: "How much can we trust meta-analyses findings? The case of antipsychotics and life-threatening adverse events." The European Congress on Assertive Outreach 2019, Verona (Italy);
16. 23/8/2019: "Antipsychotic use and risk of life-threatening medical events: umbrella review of systematic reviews of observational studies." The World Psychiatry Association Congress 2019, Lisbon (Portugal);
17. 8/6/2019: "Advances in clinical epidemiology: assessing the credibility of evidence generated by umbrella reviews". ENMESH 2019, Lisbon (Portugal).

*Organiser of national and international scientific events*

1. Optimizing mental health care in poor resource settings: a global challenge - Marie Skłodowska Curie Fellowship Closing Seminar. September 25, 2025, Aula Magna Gavazzi, via Bengasi 4, Verona

*Moderator of scientific sessions at national and international conferences*

1. 8/4/2024, Chair of the e-Poster Presentation “Rehabilitation and psychoeducation” at the 32<sup>nd</sup> European Congress of Psychiatry. Budapest (Hungary).